Aquestive Therapeutics (AQST) Equity Average (2018 - 2026)

Aquestive Therapeutics' Equity Average history runs 9 years deep, the most recent figure standing at -$33.9 million for Q1 2026.

• In Q1 2026, Equity Average rose 44.08% year-over-year to -$33.9 million; the TTM figure through Mar 2026 stood at -$33.9 million (up 44.08% YoY), while the FY2025 annual figure was -$46.9 million, up 43.7% from the prior year.
• Equity Average was -$33.9 million for Q1 2026 at Aquestive Therapeutics, down from -$18.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$18.9 million in Q4 2025 to a low of -$113.9 million in Q1 2023.
• Historically, Equity Average has averaged -$73.4 million across 5 years, with a median of -$71.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 66.75% in 2024, then sank 86.01% in 2025.
• A 5-year view of Equity Average shows it stood at -$113.2 million in 2022, then increased by 7.49% to -$104.7 million in 2023, then jumped by 49.59% to -$52.8 million in 2024, then surged by 64.22% to -$18.9 million in 2025, then tumbled by 79.28% to -$33.9 million in 2026.
• The last three Equity Average figures came in at -$33.9 million (Q1 2026), -$18.9 million (Q4 2025), and -$38.3 million (Q3 2025), per Business Quant data.